Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | CCR9 | P51686 | 1/20 | 0.41 |
| ▸ | NOD2 | Q9HC29 | 2/20 | 0.40 |
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.40 |
| ▸ | OXER1 | Q8TDS5 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31095788 | 0.92 | NOD2 (0.45) | ALDH1A1USP30CCR9NOD2NOD1 | |
| SCHEMBL3371321 | 0.82 | USP30 (0.49) | USP30CCR9NR1H2 | |
| SCHEMBL30071461 | 0.82 | USP30 (0.49) | USP30CCR9NR1H2 | |
| SCHEMBL1313682 | 0.82 | NOD2 (0.45) | ALDH1A1USP30NOD2NOD1LMNA | |
| SCHEMBL5623839 | 0.79 | NOD2 (0.52) | ALDH1A1CCR9NOD2NOD1SMN1; SMN2 | |
| SCHEMBL27247821 | 0.79 | USP30 (0.47) | USP30CCR9NR1H2MCL1 | |
| SCHEMBL3076889 | 0.78 | PRMT5 (0.38) | USP30NOD2NOD1MEN1KMT2A | |
| SCHEMBL3091728 | 0.78 | LMNA (0.49) | ALDH1A1NOD2NOD1LMNASMN1; SMN2 | |
| SCHEMBL13173591 | 0.78 | NOD2 (0.46) | ALDH1A1NOD2NOD1LMNASMN1; SMN2 | |
| SCHEMBL26683840 | 0.78 | L3MBTL1 (0.44) | ALDH1A1USP30CCR9OXER1NR1H2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MTOR, PIK3CA, PIK3CD | ALDH1A1 2519/4885USP30 4369/4885CCR9 3823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.